As of September 18, 2026, AUROPHARMA is trading at ₹1734.0, with a generally bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators show the price above key moving averages and the Supertrend, suggesting an uptrend is in place. The daily timeframe shows an ADX of 23.29, indicating a developing trend, with the plus DI (28.12) above the minus DI (14.62). Similarly, the weekly and monthly timeframes exhibit stronger trending signals with higher ADX values (40.72 and 29.33, respectively) and bullish Supertrend directions. Recent market activity shows a mix of positive and neutral attention events over the past 30 days. The stock is positioned at the upper end of its recent trading range, with a distance of 0.0% from the available high and 0.7% from the available low in its 20-period range. Annualized volatility stands at 29%, with an Average True Range (ATR) of 2.36% of the current price.

Key patterns observed include an active Hammer pattern on the monthly chart and an active Outside Bar on the weekly chart, both as of September 18, 2026. These patterns, alongside the bullish price action across timeframes, suggest potential for continued upward momentum, though the proximity to resistance levels warrants attention. The nearest identified support is ₹1730.4, which is very close to the current price, followed by ₹1710.2. The nearest resistance is noted at ₹1768.5.

In the week ending September 18, 2026, Aurobindo Pharma was featured in analyst reports highlighting potential upside. JM Financial maintained a Buy rating on the company on September 16, 2026, citing expectations of stronger earnings growth, business diversification, and new product launches. They projected up to a 28% upside over the next 12 months. Separately, on September 18, 2026, a financial news outlet included Aurobindo Pharma among stocks to trade, listing key levels and target prices, though specific details were not provided in the summary. The broader market saw pharma shares snapping a five-day losing streak on September 17, 2026, amidst cautious investor sentiment due to potential US interest rate hikes.

As of September 18, 2026, Aurobindo Pharma (AUROPHARMA) on the NSE has seen a recent price increase, trading at ₹1734.0 compared to its previous price of ₹1690.0. This shift occurred amidst news that included Aurobindo Pharma among stocks identified for trading, with specific mention of key levels, target prices, and stop losses. The company's profile as listed on the NSE remains unchanged.

Aurobindo Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) on September 15, 2026, for its Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg. This marks the company's entry into complex respiratory therapies with its first metered-dose inhaler product, slated for launch in upcoming quarters. The US market for this product was valued at US$301 million for the twelve months ending July 2026. Additionally, the USFDA completed an inspection of Apitoria Pharma Private Limited's Unit-II API facility in Telangana on September 15, 2026, with one procedural observation noted, to which the company will respond. The company also has several investor and analyst meetings scheduled between September 17 and September 22, 2026, to discuss business updates, with assurances that no unpublished price-sensitive information will be disclosed.

Aurobindo Pharma's reported results show a recent upward trend in revenue, reaching ₹9,150.35 crore in Q1 FY2026-27. This revenue growth has been accompanied by an increase in expenses, which rose to ₹7,857.77 crore in the same period. Profit Before Tax (PBT) saw a notable increase to ₹1,516.63 crore in Q1 FY2026-27, up from ₹1,338.15 crore in Q3 FY2025-26. Consequently, the net profit, or Profit Loss For Period, also grew to ₹1,032.03 crore in Q1 FY2026-27. Basic Earnings Per Share (EPS) followed this trend, increasing to ₹17.86 per share in Q1 FY2026-27. However, Comprehensive Income for the period showed some volatility, declining to ₹985.16 crore in Q1 FY2026-27 after a significant jump to ₹1,711.40 crore in Q4 FY2025-26. The company's operating performance appears to be improving, with revenue and net profit showing sequential growth.

Aurobindo Pharma's technical indicators suggest a positive trend across multiple timeframes. The daily, weekly, and monthly trends are all indicated as bullish, with the Supertrend indicator showing a bullish direction on all three. The closing price of ₹1734.0 on September 18, 2026, is above the 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs) for the daily timeframe. The stock has also shown significant positive returns over the past year, with a 1-year return of 0.54 and a Year-to-Date (YTD) return of 0.45.

While recent market commentary indicates potential upside for Aurobindo Pharma, a review of its technical indicators reveals some cautionary signals. The company's stock has experienced significant price appreciation over the past year, with a 1-year return of 0.54. However, its maximum drawdown stands at -0.24, suggesting periods of notable decline. The annualized volatility is 0.29, and downside deviation is 0.18, indicating a degree of price fluctuation that investors should monitor.